HTERT/survivin/CMV multipeptide vaccine (Abramson Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHTERT/survivin/CMV multipeptide vaccine (Abramson Cancer Center)
Drug Alias NamehTERT/survivin/CMV multipeptide vaccine (breast cancer)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionTelomerase reverse transcriptase modulators
TargetsTelomerase reverse transcriptase
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A